ExoLytics is an early-stage biotechnology startup focused on developing novel, innovative, and disruptive technologies to combat drug-resistant bacterial diseases. The Company harnesses endolysins, enzymes present in nature, to engineer safe, rapid, targeted, and effective antimicrobial therapies. The rise in antimicrobial drug resistance (AMR), coupled with shrinking treatment options, will challenge global public health and create new, untapped, market opportunities. ExoLytics aims to play a critical role in worldwide efforts to develop and commercialize alternatives to antibiotics.
